Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trial
Official title:
Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a demyelinating chronic progressive or relapsing neuropathy believed to be secondary to an autoimmune response against peripheral nerve antigens.5 We have observed two patients with CIDP with decreased corneal sensation who also suffered neurotrophic corneal ulcers and severe visual loss in the affected eyes. We want to explore the relationship of CIDP and corneal sensitivity. Our hypothesis is that people with CIDP have decreased corneal sensation compared to those without. We plan to perform a prospective study measuring corneal sensation in patients (proposed n=10) with CIDP and without to determine (1) if a difference exists in patients with CIDP compared to controls and (2) the magnitude of the difference. If a difference is detected in corneal sensitivity in patients with CIDP, this awareness amongst physicians and patients may help prevent blinding complications.
INTRODUCTION The prevalence of CIDP ranges from 0.8 to 8.4 per 100 000.5 This broad range may
reflect the use of different diagnostic criteria, as recently confirmed by an epidemiologic
study on UK population. Over 50% of the patients may have temporary severe disability during
the course of their disease and approximately 10% eventually become persistently disabled or
die because of the illness.
CIDP may affect any nerve plexus in the body. However, diagnostic criteria leans towards
nerve conduction studies in the limbs and denervation in other organ systems might be
overlooked. Sensory innervation of the cornea is provided by the ophthalmic branch of the
trigeminal nerve via the anterior ciliary nerves. A relatively small number (50-450) of
primary sensory neurons from the ipsilateral trigeminal ganglion send their peripheral axons
to the cornea and branch extensively within the corneal tissue. To maintain corneal
transparency, all peripheral axons of corneal neurons lose the myelin sheath when they enter
the corneal stroma. Fibers spread in a radial fashion parallel to the corneal surface.1
Our proposed study will explore the relationship of decreased corneal sensation, a
potentially devastating eye condition secondary to CIDP. Decreased corneal sensation may lead
to neurotrophic keratitis; which describes corneal diseases due to impairment or loss of
corneal sensation leading to epithelial defects and corneal ulcers. This may be caused by
many ocular and systemic diseases such as Diabetes or Stroke. Corneal innervation is
important for the maintenance of corneal structure and function, and provides protective
mechanisms against factors that might be potentially damaging to the cornea. Innervation also
plays an important trophic function in corneal repair in relation to disease, trauma or
surgery. Denervation and decreased corneal sensitivity are associated with impairment of
epithelial and endothelial cell function, increased epithelial and endothelial permeability,
decreased cell migration and cell mitosis. In addition, denervated corneas are predisposed to
epithelial or stromal abnormalities, recurrent erosion, impaired wound healing and
infection.2
Although corneal nerves lose their myelin sheath as they enter the stroma, the association of
a demyelinating disease affecting these nerves cannot be excluded. This may be because
trigeminal nerves can be affected at different levels (the nucleus in the pons, the Gasserian
ganglion, the trigeminal ophthalmic branch, the nasociliary nerve, or the long ciliary
nerve). Also, nerves without central myelin throughout their length can be affected in CIDP.
For example, CNVIII has peculiar myelin as it has central myelin for the majority of its
length, except for a short distal segment which has peripheral myelin.6 There is one case
report correlating findings of hearing loss and vestibular dysfunction for over a 6-year
period in patients with CIDP.
OUR STUDY
We plan a prospective clinical trial to compare prevalence of decreased corneal sensation and
possible decrease in corneal nerves in patients with CIDP previously diagnosed by clinical
features and electrophysiologic data as outlined by the American Academy of Neurology10 as
compared to patients without CIDP. Patients will be categorized according to the severity of
the disease and duration as per their medical records. Exclusion criteria is aimed at those
conditions which may reduce corneal sensation such as previous eye trauma, surgery, contact
lens use, eye drop use, or previous viral infections of the eye. A routine complete eye exam
will be performed along with additional testing for corneal sensation using a standard
method. If significant findings are obtained during initial eye exam, subjects will obtain
in-vivo confocal imaging at a second site to image corneal nerve fibers. Published standards
for corneal sensitivity as well as corneal nerve fiber density via confocal imaging will be
used in statistical analysis.
SIGNIFICANCE OF THIS STUDY
Experimental evidence indicates that impairment of corneal sensory nerves induces
pathological changes in the anatomic integrity and function of the cornea, particularly in
the epithelium. Loss of corneal sensory innervations leads to a decrease in thickness of the
corneal epithelium, intracellular swelling, loss of microvilli and abnormal production of the
basal lamina. This may lead to impairment in vitality, metabolism, and mitosis of epithelial
cells and, consequently, epithelial breakdown. Persistent epithelial defects may lead to
chronic ulceration and eventually to compromise of all ocular surface components with severe
visual impairment.
If an association is found between CIDP and decreased corneal sensation, this study will be
the first one to demonstrate such an association. An increased awareness among physicians
about this association may lead to a more careful eye exam in patients with CIDP and
detection of early changes of ocular disease which may be treated earlier so that serious
blinding complications can be avoided.
FUTURE STUDIES
If a positive association is found between CIDP and decreased corneal sensation, the latter
may be added as a supportive criteria in grading the severity of CIDP. CIDP has many
treatment modalities available according to its severity and clinical course. Finding
decreased corneal sensation in CIDP patients prospectively may lead to a diagnosis of
increased disease severity and patients may benefit from more aggressive treatments.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02465359 -
Subcutaneous Immunoglobulin for CIDP
|
N/A | |
Recruiting |
NCT05584631 -
IVIG vs SCIG in CIDP
|
Phase 1 | |
Withdrawn |
NCT01236456 -
High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 2 | |
Terminated |
NCT03779828 -
Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP
|
||
Completed |
NCT01184846 -
Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 3 | |
Recruiting |
NCT05011006 -
NT-3 Levels and Function in Individuals With CMT
|
||
Recruiting |
NCT06290141 -
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
|
Phase 3 | |
Completed |
NCT02414490 -
IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements
|
||
Completed |
NCT01545076 -
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
|
Phase 3 | |
Active, not recruiting |
NCT00716066 -
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
|
Phase 2 | |
Recruiting |
NCT04672733 -
Hizentra® in Inflammatory Neuropathies - pHeNIx Study
|
||
Not yet recruiting |
NCT04480450 -
Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 2 | |
Completed |
NCT01931644 -
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
|
||
Not yet recruiting |
NCT05219383 -
Clinical and Electrophysiological Patterns of Chronic Dysimmune Polyneuropathy
|
||
Completed |
NCT02111590 -
Immunoglobulin Dosage and Administration Form in CIDP and MMN
|
N/A | |
Recruiting |
NCT04292834 -
A Registered Cohort Study of Immune-Mediated Neuropathies
|
||
Terminated |
NCT03772717 -
Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
|
N/A | |
Completed |
NCT00278629 -
Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 2 | |
Recruiting |
NCT02372149 -
IVIg for Demyelination in Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT00962429 -
Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 2 |